Literature DB >> 17688903

Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein.

Hua-Poo Su1, Joseph W Golden, Apostolos G Gittis, Jay W Hooper, David N Garboczi.   

Abstract

Medical countermeasures to prevent or treat smallpox are needed due to the potential use of poxviruses as biological weapons. Safety concerns with the currently available smallpox vaccine indicate a need for research on alternative poxvirus vaccine strategies. Molecular vaccines involving the use of proteins and/or genes and recombinant antibodies are among the strategies under current investigation. The poxvirus L1 protein, encoded by the L1R open reading frame, is the target of neutralizing antibodies and has been successfully used as a component of both protein subunit and DNA vaccines. L1-specific monoclonal antibodies (e.g., mouse monoclonal antibody mAb-7D11, mAb-10F5) with potent neutralizing activity bind L1 in a conformation-specific manner. This suggests that proper folding of the L1 protein used in molecular vaccines will affect the production of neutralizing antibodies and protection. Here, we co-crystallized the Fab fragment of mAb-7D11 with the L1 protein. The crystal structure of the complex between Fab-7D11 and L1 reveals the basis for the conformation-specific binding as recognition of a discontinuous epitope containing two loops that are held together by a disulfide bond. The structure of this important conformational epitope of L1 will contribute to the development of molecular poxvirus vaccines and also provides a novel target for anti-poxvirus drugs. In addition, the sequence and structure of Fab-7D11 will contribute to the development of L1-targeted immunotherapeutics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17688903      PMCID: PMC2100026          DOI: 10.1016/j.virol.2007.06.042

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  44 in total

1.  Poxvirus multiprotein entry-fusion complex.

Authors:  Tatiana G Senkevich; Suany Ojeda; Alan Townsley; Gretchen E Nelson; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-08       Impact factor: 11.205

2.  Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.

Authors:  M C Galmiche; J Goenaga; R Wittek; L Rindisbacher
Journal:  Virology       Date:  1999-02-01       Impact factor: 3.616

Review 3.  Antibody-antigen complexes.

Authors:  D R Davies; E A Padlan; S Sheriff
Journal:  Annu Rev Biochem       Date:  1990       Impact factor: 23.643

4.  Cross-validated maximum likelihood enhances crystallographic simulated annealing refinement.

Authors:  P D Adams; N S Pannu; R J Read; A T Brünger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

5.  Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene.

Authors:  Lydia Aldaz-Carroll; J Charles Whitbeck; Manuel Ponce de Leon; Huan Lou; Lewis K Pannell; Jacob Lebowitz; Christiana Fogg; Christine L White; Bernard Moss; Gary H Cohen; Roselyn J Eisenberg
Journal:  Virology       Date:  2005-10-10       Impact factor: 3.616

6.  Vaccinia virus A21 virion membrane protein is required for cell entry and fusion.

Authors:  Alan C Townsley; Tatiana G Senkevich; Bernard Moss
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

7.  Identification of a vaccinia virus penetration protein.

Authors:  Y Ichihashi; T Takahashi; M Oie
Journal:  Virology       Date:  1994-08-01       Impact factor: 3.616

8.  A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.

Authors:  Yuhong Xiao; Lydia Aldaz-Carroll; Alexandra M Ortiz; J Charles Whitbeck; Edward Alexander; Huan Lou; Heather L Davis; Thomas J Braciale; Roselyn J Eisenberg; Gary H Cohen; Stuart N Isaacs
Journal:  Vaccine       Date:  2006-10-17       Impact factor: 3.641

9.  A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies.

Authors:  E J Wolffe; S Vijaya; B Moss
Journal:  Virology       Date:  1995-08-01       Impact factor: 3.616

10.  Conditional lethal expression of the vaccinia virus L1R myristylated protein reveals a role in virion assembly.

Authors:  M P Ravanello; D E Hruby
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

View more
  28 in total

Review 1.  Poxvirus proteomics and virus-host protein interactions.

Authors:  Kim Van Vliet; Mohamed R Mohamed; Leiliang Zhang; Nancy Yaneth Villa; Steven J Werden; Jia Liu; Grant McFadden
Journal:  Microbiol Mol Biol Rev       Date:  2009-12       Impact factor: 11.056

2.  Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases.

Authors:  David T Hickman; María Pilar López-Deber; Dorin Mlaki Ndao; Alberto B Silva; Deepak Nand; Maria Pihlgren; Valérie Giriens; Rime Madani; Annie St-Pierre; Hristina Karastaneva; Luitgard Nagel-Steger; Dieter Willbold; Detlev Riesner; Claude Nicolau; Marc Baldus; Andrea Pfeifer; Andreas Muhs
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

3.  Structural and biochemical characterization of the vaccinia virus envelope protein D8 and its recognition by the antibody LA5.

Authors:  Michael H Matho; Matt Maybeno; Mohammed Rafii-El-Idrissi Benhnia; Danielle Becker; Xiangzhi Meng; Yan Xiang; Shane Crotty; Bjoern Peters; Dirk M Zajonc
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

4.  Structure-function characterization of three human antibodies targeting the vaccinia virus adhesion molecule D8.

Authors:  Michael H Matho; Andrew Schlossman; Iuliia M Gilchuk; Greg Miller; Zbigniew Mikulski; Matthias Hupfer; Jing Wang; Aruna Bitra; Xiangzhi Meng; Yan Xiang; Tom Kaever; Tzanko Doukov; Klaus Ley; Shane Crotty; Bjoern Peters; Linda C Hsieh-Wilson; James E Crowe; Dirk M Zajonc
Journal:  J Biol Chem       Date:  2017-11-09       Impact factor: 5.157

5.  The myristate moiety and amino terminus of vaccinia virus l1 constitute a bipartite functional region needed for entry.

Authors:  Chwan Hong Foo; J Charles Whitbeck; Manuel Ponce-de-León; Wan Ting Saw; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2012-03-07       Impact factor: 5.103

Review 6.  Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens.

Authors:  Magdalini Moutaftsi; David C Tscharke; Kerrie Vaughan; David M Koelle; Lawrence Stern; Mauricio Calvo-Calle; Francis Ennis; Masanori Terajima; Gerd Sutter; Shane Crotty; Ingo Drexler; Genoveffa Franchini; Jon W Yewdell; Steven R Head; Janice Blum; Bjoern Peters; Alex Sette
Journal:  Future Microbiol       Date:  2010-02       Impact factor: 3.165

7.  Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.

Authors:  Jay W Hooper; Anthony M Ferro; Joseph W Golden; Peter Silvera; Jeanne Dudek; Kim Alterson; Max Custer; Bryan Rivers; John Morris; Gary Owens; Jonathan F Smith; Kurt I Kamrud
Journal:  Vaccine       Date:  2009-10-13       Impact factor: 3.641

8.  Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein.

Authors:  Thomas Kaever; Xiangzhi Meng; Michael H Matho; Andrew Schlossman; Sheng Li; Inbal Sela-Culang; Yanay Ofran; Mark Buller; Ryan W Crump; Scott Parker; April Frazier; Shane Crotty; Dirk M Zajonc; Bjoern Peters; Yan Xiang
Journal:  J Virol       Date:  2014-07-16       Impact factor: 5.103

9.  Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge.

Authors:  Christiana N Fogg; Jeffrey L Americo; Patricia L Earl; Wolfgang Resch; Lydia Aldaz-Carroll; Roselyn J Eisenberg; Gary H Cohen; Bernard Moss
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

10.  Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.

Authors:  Kaori Shinoda; Linda S Wyatt; Kari R Irvine; Bernard Moss
Journal:  Virol J       Date:  2009-03-03       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.